Overview

Safety and Tolerability of Valsartan in Children 6 to 17 Years of Age

Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the long-term safety and tolerability profile of valsartan and valsartan-based treatments in children with hypertension, with or without chronic kidney disease.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Amlodipine
Hydrochlorothiazide
Valsartan